Virios Therapeutics, Inc. - VIRI STOCK NEWS

Virios Therapeutics (Nasdaq: VIRI) announced that CEO Greg Duncan will present a company overview at the SNN Network Summer Virtual Conference on August 19, 2021, at 9:00 a.m. ET. The presentation will cover activated viruses and their link to conditions like fibromyalgia, irritable bowel syndrome, and fatigue-related disorders. Additionally, Virios is currently enrolling participants in a Phase 2b clinical trial for fibromyalgia.

Management will also be available for one-on-one meetings during the conference.

Virios Therapeutics (Nasdaq: VIRI) recently featured Chairman and CEO Greg Duncan on Bloomberg TV's The RedChip Money Report. The interview highlighted the company's innovative antiviral research, specifically the ongoing Phase 2b clinical trial for its lead candidate IMC-1, aimed at treating fibromyalgia. IMC-1 combines famciclovir and celecoxib to target herpes virus-related symptoms. The drug has received FDA fast track designation, and prior Phase 2a results indicate potential efficacy. For replay details, visit the company's investor page.

Virios Therapeutics (Nasdaq: VIRI) is set to release its second-quarter financial results on August 12, 2021, before market opening. A conference call will follow at 8:30 a.m. ET to discuss the results and provide corporate updates. Virios focuses on developing antiviral therapies for chronic diseases, with its lead candidate, IMC-1, targeting fibromyalgia by suppressing Herpes Simplex Virus-1 replication. IMC-1 has shown promise in earlier trials and is currently undergoing a Phase 2b trial, receiving FDA fast track designation.

Virios Therapeutics (Nasdaq: VIRI) announced the activation of all 41 sites for its 460-patient Phase 2b fibromyalgia (FM) trial, following positive outcomes from a previous Phase 2a trial. The trial investigates IMC-1, a proprietary combination of famciclovir and celecoxib, aimed at managing FM symptoms by targeting Herpes Simplex Virus-1 (HSV-1). IMC-1 demonstrated significant pain reduction and improved tolerability compared to placebo in Phase 2a. Top-line results from the current FORTRESS trial are expected in mid-2022.

Virios Therapeutics (Nasdaq: VIRI) announced promising results from its Phase 2a clinical trial for IMC-1, which showed better tolerability compared to placebo in fibromyalgia patients. The trial indicated lower adverse event rates and higher treatment completion rates for IMC-1. This novel therapy combines famciclovir and celecoxib to target Herpes Simplex Virus-1, potentially addressing the unmet medical needs of 10-20 million FM patients in the U.S. The results were presented at the International Association for the Study of Pain World Congress.

Virios Therapeutics (Nasdaq: VIRI) announced the dosing of the first patient in its Phase 2b FORTRESS trial, which evaluates IMC-1 for fibromyalgia treatment. IMC-1 is a proprietary antiviral therapy combining famciclovir and celecoxib, intended to suppress Herpes Simplex Virus-1 (HSV-1) activation. The trial aims to enroll approximately 460 patients and will assess pain reduction and other health metrics over 16 weeks. Results are expected by mid-2022, and the company holds a U.S. patent for this drug combination.

Virios Therapeutics, Inc. (Nasdaq: VIRI) announced that data from its Phase 2a trial of IMC-1 for fibromyalgia (FM) is being presented at the EULAR Congress. IMC-1, a combination of famciclovir and celecoxib, aims to suppress Herpes Simplex Virus-1 activation, potentially alleviating FM symptoms. The trial met primary endpoints of improved tolerability and pain reduction, with significant improvements in overall FM-related symptoms such as stiffness, sleep quality, and anxiety. These results suggest IMC-1 could be a valuable treatment for FM, currently undergoing a Phase 2b trial called FORTRESS.

Virios Therapeutics (Nasdaq: VIRI) presented significant clinical data at the virtual Digestive Disease Week 2021. The study revealed a notable increase of actively replicating herpes simplex virus type 1 (HSV-1) in the gastric mucosa of patients with functional gastrointestinal disorders (FGID) and fibromyalgia (FM) compared to controls. This suggests HSV-1 may be a root cause of chronic gastrointestinal issues. The findings promote the potential of IMC-1, a combination antiviral therapy, in treating these conditions. Further research on the HSV-1 and FGID association is planned.

Virios Therapeutics (Nasdaq: VIRI) reported its Q1 2021 financial results, highlighting significant progress in its Phase 2b fibromyalgia trial, FORTRESS, with results expected in mid-2022. The company has onboarded over 40 clinical trial sites and received acceptance for new analyses to be presented at major medical conferences. Financially, R&D expenses surged to $1.71 million from $0.03 million year-over-year. The net loss increased to $3.1 million, or ($0.37) per share, while cash reserves stood at $24.6 million, sufficient to fund operations through late 2022.